Neuroimaging in psychiatric pharmacogenetics research: The promise and pitfalls

Neuropsychopharmacology

Volumn 38, Issue 12, 2013, Pages 2327-2337

  Falcone, Mary ^a,b   Smith, Ryan M ^c   Chenoweth, Meghan J ^d   Kumar Bhattacharjee, Abesh ^e   Kelsoe, John R ^e   Tyndale, Rachel F ^d   Lerman, Caryn ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c OHIO STATE UNIVERSITY   (United States)

^d UNIVERSITY OF TORONTO   (Canada)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

neuroimaging; pharmacogenetics; psychiatry; treatment

Indexed keywords

ANTIDEPRESSANT AGENT; CANNABIS; DEXAMPHETAMINE; ESCITALOPRAM; LITHIUM; METHYLPHENIDATE; NALTREXONE; NICOTINE; NICOTINE PATCH; OLANZAPINE; PAROXETINE; VALPROIC ACID;

ASSOCIATION; ATTENTION DEFICIT DISORDER; BIPOLAR DEPRESSION; BIPOLAR DISORDER; BRAIN BLOOD FLOW; CLINICAL PROTOCOL; COGNITION; DRUG METABOLISM; EMOTION; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR DEPRESSION; MEDICAL RESEARCH; MENTAL DISEASE; NEUROIMAGING; NEUROPSYCHIATRY; NUCLEAR MAGNETIC RESONANCE IMAGING; PERFUSION WEIGHTED IMAGING; PHARMACOGENETICS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PSYCHIATRIC TREATMENT; REVIEW; SCHIZOPHRENIA; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TASK PERFORMANCE; WORKING MEMORY;

HUMANS; MENTAL DISORDERS; MENTAL PROCESSES; NEUROIMAGING; PHARMACOGENETICS;

EID: 84888390310     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2013.152     Document Type: Review

References (88)

1. Alexopoulos GS, Glatt CE, Hoptman MJ, Kanellopoulos D, Murphy CF, Kelly RE Jr et al (2010). BDNF val66met polymorphism, white matter abnormalities and remission of geriatric DEpression. J Affect Disord 125: 262-268.
2. Apud JA, Mattay V, Chen J, Kolachana BS, Callicott JH, Rasetti R et al (2007). Tolcapone improves cognition and cortical information processing in normal human subjects. Neuropsychopharmacol 32: 1011-1020. (Pubitemid 46631983)
3. Arnone D, McKie S, Elliott R, Thomas EJ, Downey D, Juhasz G et al (2012). Increased amygdala responses to sad but not fearful faces in major DEpression: relation to mood state and pharmacological treatment. Am J Psychiatr 169: 841-850.
4. Asghari V, Sanyal S, Buchwaldt S, Paterson A, Jovanovic V, Van Tol HH (1995). Modulation of intracellular cyclic AMP levels by different human dopamine D4 receptor variants. J Neurochem 65: 1157-1165.
5. Ashare RL, Falcone M, Lerman C (2013). Cognitive function during nicotine withdrawal: implications for nicotine DEpenDEnce. Neuropharmacology; epub ahead of print 29 April 2013. doi:10.1016/j.neuropharm.2013.04.034.
6. BeneDEtti F, Bollettini I, Barberi I, Radaelli D, Poletti S, Locatelli C et al (2013). Lithium and GSK3-beta promoter gene variants influence white matter microstructure in bipolar disorDEr. Neuropsychopharmacol 38: 313-327.
7. Bennett CM, Miller MB (2010). How reliable are the results from functional magnetic resonance imaging Ann NY Acad Sci 1191: 133-155.
8. Bertolino A, Caforio G, Blasi G, DE Candia M, Latorre V, Petruzzella V et al (2004). Interaction of COMT (Val(108/158)Met) genotype and olanzapine treatment on prefrontal cortical function in patients with schizophrenia. Am J Psychiatr 161: 1798-1805. (Pubitemid 39314673)
9. Bierut LJ, Stitzel JA, Wang JC, Hinrichs AL, Grucza RA, Xuei X et al (2008). Variants in nicotinic receptors and risk for nicotine DEpenDEnce. Am J Psychiatr 165: 1163-1171.
10. Blasi G, Napolitano F, Ursini G, Taurisano P, Romano R, Caforio G et al (2011). DRD2/AKT1 interaction on D2 c-AMP inDEpenDEnt signaling, attentional processing, and response to olanzapine treatment in schizophrenia. Proc Natl Acad Sci USA 108: 1158-1163.
11. Brody AL, ManDElkern MA, Olmstead RE, Scheibal D, Hahn E, Shiraga S et al (2006). Gene variants of brain dopamine pathways and smoking-induced dopamine release in the ventral caudate/nucleus accumbens. Arch Gen Psychiatr 63: 808-816.
12. Cardoner N, Soria V, Gratacos M, HernanDEz-Ribas R, Pujol J, Lopez-Sola M et al (2013). Val66met Bdnf genotypes in melancholic DEpression: effects on brain structure and treatment outcome. DEpress Anxiety 30: 225-233.
13. Carpentier PJ, Arias Vasquez A, Hoogman M, Onnink M, Kan CC, Kooij JJ et al (2012). Shared and unique genetic contributions to attention DEficit/hyperactivity disorDEr and substance use disorDErs: A pilot study of six candidate genes. Eu Neuropsychopharmacol 23: 448-457.
14. Carter CS, Barch DM, Committee CE (2012). Imaging biomarkers for treatment DEvelopment for impaired cognition: report of the sixth CNTRICS meeting: biomarkers recommenDEd for further DEvelopment. Schizophr Bull 38: 26-33.
15. Chen CH, Suckling J, Ooi C, Fu CH, Williams SC, Walsh ND et al (2008a). Functional coupling of the amygdala in DEpressed patients treated with antiDEpressant medication. Neuropsychopharmacol 33: 1909-1918. (Pubitemid 351832606)
16. Chen X, Williamson VS, An SS, Hettema JM, Aggen SH, Neale MC et al (2008b). Cannabinoid receptor 1 gene association with nicotine DEpenDEnce. Arch Gen Psychiatr 65: 816-824. (Pubitemid 351957707)
17. Chen J, Xu Y, Zhang J, Liu Z, Xu C, Zhang K et al (2012). Genotypic association of the DAOA gene with resting-state brain activity in major DEpression. Mol Neurobiol 46: 361-373.
18. Cheon KA, Ryu YH, Kim JW, Cho DY (2005). The homozygosity for 10-repeat allele at dopamine transporter gene and dopamine transporter DEnsity in Korean children with attention DEficit hyperactivity disorDEr: relating to treatment response to methylphenidate. Eu Neuropsychopharmacol 15: 95-101.
19. Chiang KP, Gerber AL, Sipe JC, Cravatt BF (2004). Reduced cellular expression and activity of the P129T mutant of human fatty acid amiDE hydrolase: eviDEnce for a link between DEfects in the endocannabinoid system and problem drug use. Hum Mol Genet 13: 2113-2119. (Pubitemid 39377833)
20. Domschke K, Dannlowski U, Hohoff C, Ohrmann P, Bauer J, Kugel H et al (2010). NeuropeptiDE Y (NPY) gene: Impact on emotional processing and treatment response in anxious DEpression. Eu Neuropsychopharmacol 20: 301-309.
21. Domschke K, Dannlowski U, Ohrmann P, Lawford B, Bauer J, Kugel H et al (2008). Cannabinoid receptor 1 (CNR1) gene: impact on antiDEpressant treatment response and emotion processing in major DEpression. Eu Neuropsychopharmacol 18: 751-759.
22. Drevets WC, Bogers W, Raichle ME (2002). Functional anatomical correlates of antiDEpressant drug treatment assessed using PET measures of regional glucose metabolism. Eu Neuropsychopharmacol 12: 527-544. (Pubitemid 35408704)
23. Durston S (2010). Imaging genetics in ADHD. NeuroImage 53: 832-838.
24. EDEnberg HJ, Dick DM, Xuei X, Tian H, Almasy L, Bauer LO et al (2004). Variations in GABRA2, encoding the alpha 2 subunit of the GABA(A) receptor, are associated with alcohol DEpenDEnce and with brain oscillations. Am J Hum Genet 74: 705-714. (Pubitemid 38420099)
25. Egan MF, Goldberg TE, Kolachana BS, Callicott JH, Mazzanti CM, Straub RE et al (2001). Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia. PNAS USA 98: 6917-6922. (Pubitemid 32538317)
26. Egan MF, Kojima M, Callicott JH, Goldberg TE, Kolachana BS, Bertolino A et al (2003). The BDNF val66met polymorphism affects activity-DEpenDEnt secretion of BDNF and human memory and hippocampal function. Cell 112: 257-269. (Pubitemid 36144114)
27. Filbey FM, Ray L, Smolen A, Claus ED, AuDEtte A, Hutchison KE (2008). Differential neural response to alcohol priming and alcohol taste cues is associated with DRD4 VNTR and OPRM1 genotypes. Alcohol Clin Exp Res 32: 1113-1123.
28. Filbey FM, Schacht JP, Myers US, Chavez RS, Hutchison KE (2010). Individual and additive effects of the CNR1 and FAAH genes on brain response to marijuana cues. Neuropsychopharmacol 35: 967-975.
29. Franklin TR, Lohoff FW, Wang Z, Sciortino N, Harper D, Li Y et al (2009). DAT genotype modulates brain and behavioral responses elicited by cigarette cues. Neuropsychopharmacol 34: 717-728.
30. Franklin TR, Wang Z, Li Y, Suh JJ, Goldman M, Lohoff FW et al (2011). Dopamine transporter genotype modulation of neural responses to smoking cues: confirmation in a new cohort. Addict Biol 16: 308-322.
31. Fuke S, Suo S, Takahashi N, Koike H, Sasagawa N, Ishiura S (2001). The VNTR polymorphism of the human dopamine transporter (DAT1) gene affects gene expression. Pharmacogenom J 1: 152-156. (Pubitemid 33757602)
32. Goldman D, Oroszi G, Ducci F (2005). The genetics of addictions: uncovering the genes. Nat Rev Genet 6: 521-532. (Pubitemid 40910429)
33. Hafeman DM, Chang KD, Garrett AS, SanDErs EM, Phillips ML (2012). Effects of medication on neuroimaging findings in bipolar disorDEr: an updated review. Bipolar Disord 14: 375-410.
34. Hirvonen MM, Laakso A, Nagren K, Rinne JO, Pohjalainen T, Hietala J (2009). C957T polymorphism of dopamine D2 receptor gene affects striatal DRD2 in vivo availability by changing the receptor affinity. Synapse 63: 907-912.
35. Hong LE, Hodgkinson CA, Yang Y, Sampath H, Ross TJ, Buchholz B et al (2010). A genetically modulated, intrinsic cingulate circuit supports human nicotine addiction. Proc Natl Acad Sci USA 107: 13509-13514.
36. Hutchison KE, Haughey H, Niculescu M, Schacht J, Kaiser A, Stitzel J et al (2008). The incentive salience of alcohol: translating the effects of genetic variant in CNR1. Arch Gen Psychiatr 65: 841-850. (Pubitemid 351957709)
37. Hutchison KE, LaChance H, Niaura R, Bryan A, Smolen A (2002). The DRD4 VNTR polymorphism influences reactivity to smoking cues. J Abnorm Psychol 111: 134-143. (Pubitemid 34154877)
38. Jacobsen LK, Pugh KR, Mencl WE, Gelernter J (2006). C957T polymorphism of the dopamine D2 receptor gene modulates the effect of nicotine on working memory performance and cortical processing efficiency. Psychopharmacology 188: 530-540. (Pubitemid 46766441)
39. Jamadar S, Powers NR, Meda SA, Calhoun VD, Gelernter J, Gruen JR et al (2013). Genetic influences of resting state fMRI activity in language-related brain regions in healthy controls and schizophrenia patients: a pilot study. Brain Imaging Behav 7: 15-27.
40. Janes AC, Smoller JW, David SP, FreDErick BD, Haddad S, Basu A et al (2012). Association between CHRNA5 genetic variation at rs16969968 and brain reactivity to smoking images in nicotine DEpenDEnt women. Drug Alcohol DEpend 120: 7-13.
41. Jonsson EG, Nothen MM, Grunhage F, FarDE L, Nakashima Y, Propping P et al (1999). Polymorphisms in the dopamine D2 receptor gene and their relationships to striatal dopamine receptor DEnsity of healthy volunteers. Mol Psychiatr 4: 290-296. (Pubitemid 29292183)
42. Kareken DA, Liang T, Wetherill L, Dzemidzic M, Bragulat V, Cox C et al (2010). A polymorphism in GABRA2 is associated with the medial frontal response to alcohol cues in an fMRI study. Alcohol Clin Exp Res 34: 2169-2178.
43. Kessler RC, Chiu WT, DEmler O, Merikangas KR, Walters EE (2005). Prevalence, severity, and comorbidity of 12-month DSM-IV disorDErs in the National Comorbidity Survey Replication. Arch Gen Psychiatr 62: 617-627. (Pubitemid 40973437)
44. Konarski JZ, McIntyre RS, Kennedy SH, Rafi-Tari S, Soczynska JK, Ketter TA (2008). Volumetric neuroimaging investigations in mood disorDErs: bipolar disorDEr versus major DEpressive disorDEr. Bipolar Disord 10: 1-37.
45. Kwaasteniet BD, Ruhe E, Caan M, Rive M, Olabarriaga S, Groefsema M et al (2013). Relation between structural and functional connectivity in major DEpressive disorDEr. Biol Psychiatr 4: 40-47.
46. Kwok JB, Hallupp M, Loy CT, Chan DK, Woo J, Mellick GD et al (2005). GSK3B polymorphisms alter transcription and splicing in Parkinson's disease. Ann Neurol 58: 829-839. (Pubitemid 41746872)
47. Lerman C, Tyndale R, Patterson F, Wileyto EP, Shields PG, Pinto A et al (2006). Nicotine metabolite ratio predicts efficacy of transDErmal nicotine for smoking cessation. Clin Pharm Therap 79: 600-608. (Pubitemid 43817942)
48. Lesch KP, Gutknecht L (2005). Pharmacogenetics of the serotonin transporter. Prog Neuropsychoph 29: 1062-1073. (Pubitemid 41080133)
49. Lui S, Wu Q, Qiu L, Yang X, Kuang W, Chan RC et al (2011). Resting-state functional connectivity in treatment-resistant DEpression. Am J Psychiatr 168: 642-648.
50. Loughead J, Wileyto EP, ValDEz JN, Sanborn P, Tang K, Strasser AA et al (2009). Effect of abstinence challenge on brain function and cognition in smokers differs by COMT genotype. Mol Psychiatr 14: 820-826.
51. Mague SD, Blendy JA (2010). OPRM1 SNP (A118G): involvement in disease DEvelopment, treatment response, and animal moDEls. Drug Alcohol DEpend 108: 172-182.
52. Mague SD, Isiegas C, Huang P, Liu-Chen LY, Lerman C, Blendy JA (2009). Mouse moDEl of OPRM1 (A118G) polymorphism has sex-specific effects on drug-mediated behavior. Proc Natl Acad Sci USA 106: 10847-10852.
53. Malhotra AK, Zhang JP, Lencz T (2012). Pharmacogenetics in psychiatry: translating research into clinical practice. Mol Psychiatr 17: 760-769.
54. Mattay VS, Goldberg TE, Fera F, Hariri AR, Tessitore A, Egan MF et al (2003). Catechol O-methyltransferase val158-met genotype and individual variation in the brain response to amphetamine. Proc Natl Acad Sci USA 100: 6186-6191. (Pubitemid 36576952)
55. McClernon FJ, Hutchison KE, Rose JE, Kozink RV (2007). DRD4 VNTR polymorphism is associated with transient fMRI-BOLD responses to smoking cues. Psychopharmacology 194: 433-441. (Pubitemid 47492991)
56. McGuffin P, Rijsdijk F, Andrew M, Sham P, Katz R, Cardno A (2003). The heritability of bipolar affective disorDEr and the genetic relationship to unipolar DEpression. Arch Gen Psychiatr 60: 497-502. (Pubitemid 36539059)
57. Menon V (2011). Large-scale brain networks and psychopathology: a unifying triple network moDEl. Trends Cogn Sci 15: 483-506.
58. Meyer-LinDEnberg A, NicoDEmus KK, Egan MF, Callicott JH, Mattay V, Weinberger DR (2008). False positives in imaging genetics. NeuroImage 40: 655-661.
59. Meyer-LinDEnberg A, Weinberger DR (2006). Intermediate phenotypes and genetic mechanisms of psychiatric disorDErs. Nat Rev Neurosci 7: 818-827. (Pubitemid 44435264)
60. Michael AM, King MD, Ehrlich S, Pearlson G, White T, Holt DJ et al (2011). A data-driven investigation of gray matter-function correlations in schizophrenia during a working memory task. Front Hum Neurosci 5: 71.
61. Millan MJ, Agid Y, Brune M, Bullmore ET, Carter CS, Clayton NS et al (2012). Cognitive dysfunction in psychiatric disorDErs: characteristics, causes and the quest for improved therapy. Nat Rev Drug Discov 11: 141-168.
62. Pava MJ, Woodward JJ (2012). A review of the interactions between alcohol and the endocannabinoid system: implications for alcohol DEpenDEnce and future directions for research. Alcohol 46: 185-204.
63. Plichta MM, Schwarz AJ, Grimm O, Morgen K, Mier D, Haddad L et al (2012). Test-retest reliability of evoked BOLD signals from a cognitive-emotive fMRI test battery. NeuroImage 60: 1746-1758.
64. Ramchandani VA, Umhau J, Pavon FJ, Ruiz-Velasco V, Margas W, Sun H et al (2011). A genetic DEterminant of the striatal dopamine response to alcohol in men. Mol Psychiatr 16: 809-817.
65. Ray LA, Barr CS, Blendy JA, Oslin D, Goldman D, Anton RF (2012). The role of the Asn40Asp polymorphism of the mu-opioid receptor gene (OPRM1) on alcoholism etiology and treatment: a critical review. Alcohol Clin Exp Res 36: 385-394.
66. Ray R, Loughead J, Wang Z, DEtre J, Yang E, Gur R et al (2008). Neuroimaging, genetics and the treatment of nicotine addiction. Behav Brain Res 193: 159-169.
67. Ray R, Ruparel K, Newberg A, Wileyto EP, Loughead JW, Divgi C et al (2011). Human Mu-opioid Receptor (OPRM1 A118G) polymorphism is associated with brain mu-opioid receptor binding potential in smokers. Proc Natl Acad Sci USA 108: 9268-9273.
68. RohDE LA, Roman T, Szobot C, Cunha RD, Hutz MH, BieDErman J (2003). Dopamine transporter gene, response to methylphenidate and cerebral blood flow in attention-DEficit/hyperactivity disorDEr: a pilot study. Synapse 48: 87-89. (Pubitemid 36374002)
69. Rosenblau G, Sterzer P, Stoy M, Park S, FrieDEl E, Heinz A et al (2012). Functional neuroanatomy of emotion processing in major DEpressive disorDEr is altered after successful antiDEpressant therapy. J Psychopharmacol 26: 1424-1433.
70. Roussos P, Giakoumaki SG, Bitsios P (2009). Tolcapone effects on gating, working memory, and mood interact with the synonymous catechol-O- methyltransferase rs4818c/g polymorphism. Biol Psychiatr 66: 997-1004.
71. Ruhe HG, Ooteman W, Booij J, Michel MC, Moeton M, Baas F et al (2009). Serotonin transporter gene promoter polymorphisms modify the association between paroxetine serotonin transporter occupancy and clinical response in major DEpressive disorDEr. Pharmacogenet Genom 19: 67-76.
72. Savitz J, Nugent AC, Bogers W, Liu A, Sills R, Luckenbaugh DA et al (2010). Amygdala volume in DEpressed patients with bipolar disorDEr assessed using high resolution 3T MRI: the impact of medication. NeuroImage 49: 2966-2976.
73. Schacht JP, Anton RF, Voronin KE, Randall PK, Li X, HenDErson S et al (2013). Interacting effects of naltrexone and OPRM1 and DAT1 variation on the neural response to alcohol cues. Neuropsychopharmacol 38: 414-422.
74. Schnoll RA, Patterson F, Wileyto EP, Tyndale RF, Benowitz N, Lerman C (2009). Nicotine metabolic rate predicts successful smoking cessation with transDErmal nicotine: a validation study. Pharm Biochem Be 92: 6-11.
75. Sinha R, Li CS (2007). Imaging stress-and cue-induced drug and alcohol craving: association with relapse and clinical implications. Drug Alcohol Rev 26: 25-31.
76. Sommer WH, Lidstrom J, Sun H, Passer D, Eskay R, Parker SC et al (2010). Human NPY promoter variation rs16147:T4C as a moDErator of prefrontal NPY gene expression and negative affect. Hum Mutat 31: E1594-E1608.
77. Szobot CM, Roman T, Hutz MH, Genro JP, Shih MC, Hoexter MQ et al (2011). Molecular imaging genetics of methylphenidate response in ADHD and substance use comorbidity. Synapse 65: 154-159.
78. Tan HY, Chen AG, Kolachana B, Apud JA, Mattay VS, Callicott JH et al (2012). Effective connectivity of AKT1-mediated dopaminergic working memory networks and pharmacogenetics of anti-dopaminergic treatment. Brain 135(Pt 5): 1436-1445.
79. Tang DW, Hello B, Mroziewicz M, Fellows LK, Tyndale RF, Dagher A (2012). Genetic variation in CYP2A6 predicts neural reactivity to smoking cues as measured using fMRI. NeuroImage 60: 2136-2143.
80. Theberge J (2008). Perfusion magnetic resonance imaging in psychiatry. Top Magn Reson Imaging 19: 111-130.
81. Tost H, Bilek E, Meyer-LinDEnberg A (2012). Brain connectivity in psychiatric imaging genetics. NeuroImage 62: 2250-2260.
82. Tyndale RF, Payne JI, Gerber AL, Sipe JC (2007). The fatty acid amiDE hydrolase C385A (P129T) missense variant in cannabis users: studies of drug use and DEpenDEnce in Caucasians. Am J Med Genet B 144B: 660-666. (Pubitemid 47077151)
83. van Belzen MJ, Heutink P (2006). Genetic analysis of psychiatric disorDErs in humans. Genes Brain Behav 5(Suppl 2): 25-33.
84. Wang Z, Ray R, Faith M, Tang K, Wileyto EP, DEtre JA et al (2008). Nicotine abstinence-induced cerebral blood flow changes by genotype. Neurosci Lett 438: 275-280.
85. Weerts EM, McCaul ME, Kuwabara H, Yang X, Xu X, Dannals RF et al (2012). Influence of OPRM1 Asn40Asp variant (A118G) on [11C]carfentanil binding potential: preliminary findings in human subjects. Int J Neuropsychopharmacol 16: 47-53.
86. Wetherill RR, Jagannathan K, Lohoff FW, Ehrman R, O'Brien CP, Childress AR et al (2012). Neural correlates of attentional bias for smoking cues: modulation by variance in the dopamine transporter gene. Addict Biol; e-pub ahead of print. doi:10.1111/j.1369-1600.2012.00507.x.
87. Wilcox CE, Claus ED, Blaine SK, Morgan M, Hutchison KE (2013). Genetic variation in the alpha synuclein gene (SNCA) is associated with BOLD response to alcohol cues. J Studies Alcohol Drugs 74: 233-244.
88. Zhang PW, Ishiguro H, Ohtsuki T, Hess J, Carillo F, Walther D et al (2004). Human cannabinoid receptor 1: 50 exons, candidate regulatory regions, polymorphisms, haplotypes and association with polysubstance abuse. Mol Psychiatr 9: 916-931. (Pubitemid 39381956)